Pressure BioScience (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and platform-technology solutions to the worldwide life sciences and other industries, today announced that the combination of PBIO’s patented Pressure Cycling Technology (“PCT”) with RedShiftBio’s proprietary Microfluidic Modulation Spectroscopy (“MMS”) has resulted in a powerful new platform for biotherapeutic drug development (“PCT-enhanced MMS”). PBIO believes combining both platforms enables for the rigorous investigation of protein structure and stability in a highly efficient workflow that can be crucial in drug development. Per the release, the collaboration should result in faster development of new drugs as well as improvement in the quality of drugs coming onto the market. “Our collaboration with RedShiftBio takes advantage of our ability to manipulate protein structure with high pressure and RedShiftBio’s precise analytical platform that reports subtle changes in the three-dimensional structure of protein molecules that could lead to protein aggregation. Unfortunately, aggregated protein biologics could train a patient’s immune system to recognize and eliminate the drug, so finding appropriate formulations to prevent aggregation is a major task in biopharmaceutical drug development. Moreover, MMS will help us to understand protein folding kinetics in our BaroFold platform, which uses high pressure to shape recombinant proteins into their active and stable conformations in biomanufacturing process development,” Alexander V. Lazarev, Ph.D., Chief Science Officer of PBIO stated in the news release.
To view the full press release, visit http://nnw.fm/UM67p
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life-sciences industry. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure-cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented, enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). PBIO’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology) to allow entry into the biopharma contract services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and (ii) prepare higher-quality, homogenized, extended shelf-life or room-temperature, stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://nnw.fm/PBIO
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.